Select therapeutic use:
Indications for Ipratropium Bromide Inhalation Solution:
Bronchospasm associated with chronic bronchitis and emphysema.
500mcg orally by nebulization 3–4 times daily; separate doses by 6–8 hours.
Allergy to atropine or its derivatives.
Not for primary treatment of acute attack. Avoid eyes. Narrow-angle glaucoma. GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Caution with other anticholinergics.
Bronchitis, COPD exacerbation, dyspnea, headache, anticholinergic effects; paradoxical bronchospasm, hypersensitivity reactions.
Formerly known under the brand name Atrovent.
HFA (NO); soln (YES)
Inhaler—12.9g (200 inh); inhalation soln—contact supplier